沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

休市中 06-18 16:08:08

4.040

-0.060

-1.46%

最高4.160	最低3.960	成交量75.10万
今开4.120	昨收4.100	日振幅4.88%
总市值27.27亿	流通市值27.27亿	总股本6.75亿
成交额302.37万	换手率0.11%	流通股本6.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":4.04,"timestamp":1781770088009,"preClose":4.1,"halted":0,"volume":751000,"delay":0,"changeRate":-0.01463414634146332,"floatShares":675000000,"shares":675000000,"eps":-0.352834304043942,"marketStatus":"休市中","change":-0.06,"latestTime":"06-18 16:08:08","open":4.12,"high":4.16,"low":3.96,"amount":3023700,"amplitude":0.04878,"askPrice":4.04,"askSize":18000,"bidPrice":4,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.352834304043942,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":4.1,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":0.6159774881407868,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996/tweets","defaultTab":"tweets","newsList":[{"id":"2644082805","title":"阳普医疗（300030）披露全资子公司获医疗器械变更注册及延续注册公告，6月18日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644082805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644082805?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:54","pubTimestamp":1781794459,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，阳普医疗报收于6.22元，较前一交易日下跌0.16%，最新总市值为19.23亿元。该股当日开盘6.19元，最高6.33元，最低6.12元，成交额达4000.72万元，换手率为2.36%。阳普医疗于近日披露《关于全资子公司收到医疗器械变更注册（备案）文件及完成延续注册的公告》。涉及产品包括一次性使用防针刺静脉采血针、一次性使用静脉采血针的技术要求变更，以及血栓弹力图仪的延续注册，有效期至2032年5月8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800043052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","09996","300030","BK0146","BK1100","BK1574","BK0251","159883","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644704869","title":"普门科技：公司UA系列全自动特定蛋白分析仪已取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644704869","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644704869?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:42","pubTimestamp":1781775753,"startTime":"0","endTime":"0","summary":"证券之星消息，普门科技(688389)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司U系列特定蛋白分析仪计划何时投放市场？配套的试剂研发进展情况如何？普门科技回复：尊敬的投资者，您好！公司UA系列全自动特定蛋白分析仪已取得医疗器械注册证，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","09996","BK1583","BK1100","688389","BK0251","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644328772","title":"重庆市涪陵区市场监管局开展在用医疗器械使用情况专项检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2644328772","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644328772?lang=zh_cn&edition=full","pubTime":"2026-06-18 13:36","pubTimestamp":1781760960,"startTime":"0","endTime":"0","summary":"执法人员在一家医疗机构血液透析中心检查血液透析仪的检验合格标志。中国质量新闻网讯 6月17日，重庆市涪陵区市场监管局开展在用医疗器械使用情况专项检查，重点对辖区医疗机构在用医疗器械是否进行备案登记，是否在使用有效期内、涉及强检范围的医疗器材是否定期检定等进行检查。（郭星雨 文光辉）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-18/doc-inicvfcr6496750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1583","BK1574","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644732297","title":"【券商聚焦】中信建投：建议2026年加配医疗器械板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2644732297","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644732297?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:24","pubTimestamp":1781745845,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券建议，2026年加配医疗器械板块，短期来看，建议把握2026年业绩改善个股的业绩和估值修复机会，多家医疗器械行业细分赛道龙头公司将于2026年迎来加速增长，同时建议关注手术机器人、脑机接口等新科技方向，相关技术突破和商业化落地有望持续催化板块热度。长期来看，医疗器械板块投资机会来自创新、出海和并购整合，板块的创新和国际化能力得到认可，估值正在重构。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984058","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01066","06826","BK1247","BK1615","BK1574","BK1100","601066","BK1591","BK0276","01302","02235","00853","BK1502","BK1617","BK1600","BK1583","BK1189","BK1161","09996","BK1587","02190","LU0173614495.USD","BK1610","BK1142","BK1585","BK1589","BK1584","BK1501","159883","BK1515","BK1571","00241","BK1222","HK0000165453.HKD","BK1593","02252","LU0287142896.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644571407","title":"巨子生物：附属公司交联重组胶原蛋白植入剂获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644571407","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644571407?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:02","pubTimestamp":1781686920,"startTime":"0","endTime":"0","summary":"6月17日，巨子生物（02367）发布公告，全资附属公司陕西巨子生物技术有限公司交联重组胶原蛋白植入剂获医疗器械注册证。本产品采用人III型成熟胶原蛋白全长序列，该序列共1068个氨基酸，完整保留胶原蛋白的天然功能域，并采用无化学交联剂残留风险的物理交联工艺，形成稳定的三维网状凝胶，用于颈部皮内真皮层注射填充，以纠正颈部中重度横纹。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173774630013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1207","SG9999004311.SGD","BK1574","BK1100","BK1583","02367","09996","159883","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644719863","title":"中国医疗器械公司贝斯曼(BSME.US)撤回2000万美元美股IPO计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2644719863","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644719863?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:40","pubTimestamp":1781682058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国医疗器械公司贝斯曼精密仪器(BSME.US)已撤回其 IPO 计划。该公司曾于 2023 年 2 月提交上市申请，计划以 4 至 6 美元的发行价区间发行 400 万股股票，拟募资 2000 万美元。若以拟定价格区间的中位数计算，其市值原本将达到 9500 万美元。这家总部位于中国深圳的公司成立于 2001 年。截至 2024 年 6 月 30 日的 12 个月内，该公司的账面营收为 300 万美元。公司原计划在纳斯达克上市，股票代码为“BSME”，本杰明证券(Benjamin Securities)原定为此次交易的独家账簿管理人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","159883","BK1583","BK1100","BK1574","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644716052","title":"华瓷股份：公司子公司华联特陶生产的齿科产品于2024年取得FDA医疗器械资质认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644716052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644716052?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:37","pubTimestamp":1781681876,"startTime":"0","endTime":"0","summary":"公司子公司江西金环旗下子公司在氧化锆粉体研发领域已取得阶段性成果，公司子公司华联特陶生产的齿科产品于2024年取得FDA医疗器械资质认证，销往多个国家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK0235","BK1574","09996","BK1100","BK1583","001216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643765504","title":"辰光医疗（920300）披露完成《医疗器械生产许可证》变更公告，6月16日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643765504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643765504?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:51","pubTimestamp":1781621474,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，辰光医疗报收于10.87元，较前一交易日上涨2.94%，最新总市值为9.33亿元。该股当日开盘10.5元，最高11.39元，最低10.5元，成交额达3990.8万元，换手率为5.46%。近日，上海辰光医疗科技股份有限公司披露《关于完成〈医疗器械生产许可证〉变更的公告》。公告显示，公司于2026年6月16日收到上海市药品监督管理局下发的《医疗器械生产许可证》，已完成生产范围变更。许可证有效期自2025年2月24日至2030年2月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1583","BK1574","159891","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643333007","title":"港股异动 | 沛嘉医疗-B(09996)早盘涨近6% 近日与贝朗医疗签订SeQuent Please CIS独家分销权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2643333007","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643333007?lang=zh_cn&edition=full","pubTime":"2026-06-16 11:29","pubTimestamp":1781580584,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，沛嘉医疗-B早盘涨近6%，截至发稿，涨2.23%，报4.12港元，成交额401.49万港元。消息面上，沛嘉医疗近日发布公告，附属加奇生物)与贝朗医疗订立独家分销协议。根据该协议，加奇生物已取得贝朗医疗旗下产品SeQuent Please CIS紫杉醇药物涂层颅内球囊扩张导管在中国大陆地区的独家分销权。与贝朗医疗的合作进一步丰富了集团神经介入产品组合，强化了集团在创新颅内介入解决方案领域的战略布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159891","BK4585","BK1583","BK4588","VXUS","BK1574","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643070202","title":"合肥取消665家第二类医疗器械经营企业备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2643070202","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643070202?lang=zh_cn&edition=full","pubTime":"2026-06-16 00:14","pubTimestamp":1781540040,"startTime":"0","endTime":"0","summary":"据介绍，市场监管部门在执法检查中发现，部分企业在取得第二类医疗器械经营资质后，存在备案材料不真实、不在备案场所实地经营等违法违规行为，给医疗器械流通环节带来较高风险隐患。据了解，自2023年以来，合肥已累计取消8537家第二类医疗器械企业经营备案，市场秩序得到进一步规范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-16/doc-inicpmem4771218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","09996","159883","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03329","02096","LU1960683339.HKD","LU0348827113.USD","01951","LU1226287875.USD","09996","LU2399975544.HKD","06996","09926","LU2097828631.EUR","02273","06821","01530","02162","LU1880383366.USD","06990","HK0000320264.USD","LU1242518857.USD","LU0140636845.USD","02596","01952","LU0051755006.USD","LU1688375341.USD","01276","01177","01801","03759","09966","LU0181495838.USD","BK1576","HK0000306685.HKD","LU0502904849.HKD","BK1191","SG9999002562.SGD","02269","LU0456827905.SGD","02268","03692","06078","01093","LU0737861772.HKD","LU0320764599.SGD","IE00B0JY6N72.USD","LU0819121731.USD","01548","IE00BZ08YR35.GBP","06160","LU3063872942.SGD","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264164","title":"中恒集团最新公告：控股孙公司获两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264164","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642264164?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:09","pubTimestamp":1781258984,"startTime":"0","endTime":"0","summary":"中恒集团(600252.SH)公告称，公司控股孙公司海南莱美医疗器械有限公司收到海南省药品监督管理局颁发的麻醉视频喉镜及一次性使用喉镜片两项《医疗器械注册证》，有效期至2031年6月2日。该产品用于指引医护人员准确进行气道插管，有助于丰富公司医疗器械产品种类，提升综合竞争力，但实际销售情况取决于市场推广效果，对业绩影响尚不确定。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0015","BK1574","BK0012","159883","09996","BK0077","600252","BK0028","BK1100","BK1583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642263510","title":"莱美药业(300006.SZ)子公司获得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2642263510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642263510?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:59","pubTimestamp":1781251185,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司控股子公司海南莱美医疗器械有限公司(以下简称“莱美医疗器械”)收到海南省药品监督管理局颁发的两项《医疗器械注册证》，涉及产品：“麻醉视频喉镜”、“一次性使用喉镜片”。本次公司控股子公司获证的麻醉视频喉镜及一次性使用喉镜片，是莱美医疗器械研发的内窥镜产品，该产品能指引医护人员准确进行气道插管，有利于临床使用对患者病症的判断及治疗。此次公司控股子公司产品获证将进一步丰富公司医疗器械产品种类，满足市场多样化的需求，提升公司综合竞争力，对未来经营将产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0070","BK1100","BK1574","BK0239","159883","09996","300006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402985","title":"亚太药业(002370.SZ)拟设立子公司 重点探索光动力创新类药物及配套医疗器械的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402985","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642402985?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:50","pubTimestamp":1781164230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业 发布公告，根据发展战略和经营规划需要，为进一步完善公司产业发展布局，全资子公司雅泰利众拟以自有资金2000万元设立子公司浙江盛曜光研药业有限公司(暂定名)。光动力是一种利用光敏剂、特定波长光源与氧分子反应破坏病变组织的医疗技术，广泛应用于肿瘤治疗、皮肤病及部分炎症性疾病，是当下医药健康行业的前沿赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK0239","BK1583","09996","BK1574","002370","BK1100","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642150468","title":"华东医药(000963.SZ)：注射用聚己内酯微球面部填充剂医疗器械注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2642150468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642150468?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:15","pubTimestamp":1780992909,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华东医药 发布公告，2026年6月8日，公司全资子公司欣可丽美学(杭州)供应链管理有限公司收到国家药品监督管理局签发的《受理通知书》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé伊妍仕S型拓展新适用症的变更注册申请获得受理，本次申请新增适用症：用于额部皮下或骨膜上植入，以改善中至重度额部轮廓缺陷。公司后续将继续全力开展这款产品在中国的注册工作，推动其新适用症早日获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0187","BK0183","BK0188","LU1969619763.USD","LU2328871848.SGD","BK1100","BK0175","159883","BK1574","09996","BK0209","000963","BK0132","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642545453","title":"国金证券：聚焦医疗器械“创新+出海”双主线 建议重点关注2026年业绩有望加速细分龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2642545453","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642545453?lang=zh_cn&edition=full","pubTime":"2026-06-09 09:15","pubTimestamp":1780967709,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，聚焦医疗器械“创新+出海”双主线。当前医疗器械板块正迎来“基本面复苏”与“估值体系重构”的双击机遇。建议重点关注2026年业绩有望加速的细分龙头。国金证券主要观点如下：医疗器械板块当前投资应紧扣出海及创新双主线出海不仅帮助优质企业突破国内增长天花板，还能利用海外高定价市场提升盈利质量;而具备临床差异化价值的创新产品，则是抵御国内价格压力的核心护城河。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0276","600109","09996","BK0012","BK1574","BK0201","159883","BK1100","BK0028","BK0183","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641044461","title":"九强生物(300406.SZ)：两款产品取得医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641044461","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641044461?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:52","pubTimestamp":1780905120,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，涉及产品：“可溶性生长刺激表达基因2蛋白测定试剂盒(胶乳免疫比浊法)”、“全自动凝血分析仪(型号：MDC3600、 MDC2600)”。上述产品医疗器械注册证的取得，丰富了公司在体外诊断生化和凝血分析仪器细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0077","BK1100","300406","BK1583","159883","BK1574","BK0239","09996","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641665106","title":"香港医管局：香港引进药械办已投入运作 料将优化新药械及好药械引进程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2641665106","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641665106?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:46","pubTimestamp":1780897598,"startTime":"0","endTime":"0","summary":"引进药械办已于今日投入运作，将会大大加快引入“新药”及“好药”的程序，尽快纳入医管局药物名册，有效全面提升病人获得更佳治疗的机会。香港医管局表示，有信心引进药械办投入运作后，会大大优化引进创新药物及医疗器械的流程，令更多创新药物及医疗器械更快引入到公立医院供病人使用，提升治疗成效及病人福祉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09996","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116639","title":"山外山最新公告：全资子公司取得血液透析干粉医疗器械变更注册文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116639?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:45","pubTimestamp":1780649148,"startTime":"0","endTime":"0","summary":"山外山(688410.SH)公告称，公司全资子公司重庆天外天生物技术有限公司近日收到国家药监局颁发的医疗器械变更注册文件，产品为血液透析干粉，主要变更内容为产品技术要求。本次变更为常规合规性技术升级，不涉及核心配方及适用范围调整，有利于增强公司产品综合竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","BK1574","09996","BK1100","BK0251","688410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640599581","title":"乐心医疗最新公告：医疗器械注册证变更获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640599581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640599581?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:10","pubTimestamp":1780567824,"startTime":"0","endTime":"0","summary":"乐心医疗(300562.SZ)公告称，公司近日收到广东省药品监督管理局通知，申报的腕式电子血压计医疗器械注册证变更事项已获受理。本次变更新增产品型号BWZ51、BWZ52，旨在满足市场需求、扩大业务范围。该事项尚处受理阶段，后续需进一步核准认证，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400032114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK0251","BK1583","BK1574","BK1100","159883","BK0109","BK0114","300562"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":-0.0242},{"period":"1month","weight":-0.2505},{"period":"3month","weight":-0.2962},{"period":"6month","weight":-0.3344},{"period":"1year","weight":-0.3628},{"period":"ytd","weight":-0.3278}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.053778},{"month":5,"riseRate":0.6,"avgChangeRate":-0.096849},{"month":6,"riseRate":0.571429,"avgChangeRate":0.045753},{"month":7,"riseRate":0.5,"avgChangeRate":0.047595},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}